BioPharma Resources

Drug Trial Radar · NCT07318558

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Feb 16, 2026

Primary completion

Feb 25, 2033

Study completion Feb 25, 2033

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Conditions

  • Ovarian Neoplasms
  • Ovarian Cancer

Interventions

  • Sacituzumab tirumotecanDrug

    Administered via intravenous (IV) infusion at a dose of 4mg/kg

  • BevacizumabDrug

    Administered via IV infusion at a dose of 15mg/kg

  • Rescue MedicationsDrug

    Participants must receive prophylactic steroid mouthwash (dexamethasone or equivalent). It is recommended that participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 49 months

Locations

178 sites in 30 countries. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham ( Site 0058)

    Birmingham, Alabama · Recruiting

  • UCSD Moores Cancer Center ( Site 0038)

    La Jolla, California · Recruiting

  • Hoag Memorial Hospital Presbyterian ( Site 0074)

    Newport Beach, California · Recruiting

  • John Muir Health Cancer Center ( Site 0069)

    Walnut Creek, California · Recruiting

  • Anschutz Cancer Pavilion ( Site 0049)

    Aurora, Colorado · Recruiting

  • University of Colorado Health - Highlands Ranch Hospital ( Site 0094)

    Highlands Ranch, Colorado · Recruiting

  • Mount Sinai Cancer Center ( Site 0029)

    Miami Beach, Florida · Recruiting

  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)

    Orlando, Florida · Recruiting

  • Winship Cancer Institute of Emory University ( Site 0037)

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists (ICS) ( Site 8009)

    Arlington Heights, Illinois · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0055)

    Fort Wayne, Indiana · Recruiting

  • Franciscan Health Indianapolis ( Site 0081)

    Indianapolis, Indiana · Recruiting

  • Women's Cancer Care ( Site 0018)

    Covington, Louisiana · Recruiting

  • Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060)

    Scarborough, Maine · Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8002)

    Columbia, Maryland · Recruiting

  • Nebraska Methodist Hospital ( Site 0004)

    Omaha, Nebraska · Recruiting

  • University Of Nebraska Medical Center ( Site 0035)

    Omaha, Nebraska · Recruiting

  • The Center of Hope ( Site 0025)

    Reno, Nevada · Recruiting

  • Womens Cancer Care Associates, LLC ( Site 0023)

    Albany, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0072)

    New York, New York · Recruiting

  • Duke Cancer Center ( Site 0012)

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center ( Site 0042)

    Cincinnati, Ohio · Recruiting

  • The Ohio State University ( Site 0005)

    Hilliard, Ohio · Recruiting

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007)

    Tulsa, Oklahoma · Recruiting

  • Kaiser Permanente Interstate Medical Office - Central ( Site 0089)

    Portland, Oregon · Recruiting

  • Hospital of the University of Pennsylvania ( Site 0071)

    Philadelphia, Pennsylvania · Recruiting

  • AHN West Penn Hospital ( Site 0051)

    Pittsburgh, Pennsylvania · Recruiting

  • Women & Infants Hospital ( Site 0001)

    Providence, Rhode Island · Recruiting

  • West Cancer Center and Research Institute ( Site 0013)

    Germantown, Tennessee · Recruiting

  • University of Tennessee Medical Center ( Site 0087)

    Knoxville, Tennessee · Recruiting

  • Henry-Joyce Cancer Clinic ( Site 0011)

    Nashville, Tennessee · Recruiting

  • JPS Health Network ( Site 0084)

    Fort Worth, Texas · Recruiting

  • Virginia Cancer Specialists (VCS) ( Site 8012)

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates (VOA) ( Site 8013)

    Norfolk, Virginia · Recruiting

  • Hospital Britanico de Buenos Aires ( Site 2905)

    CABA, Argentina · Recruiting

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 2907)

    La Rioja, Argentina · Recruiting

  • Hospital Aleman ( Site 2903)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 2902)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Fundación Respirar ( Site 2912)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.